

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 13, 2015

**DELMAR PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

<b>Nevada</b>	<b>000-54801</b>	<b>99-0360497</b>
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

Suite 720-999 West Broadway  
Vancouver, British Columbia  
Canada V5Z 1K5  
(Address of principal executive offices) (zip code)

(604) 629-5989  
(Registrant's telephone number, including area code)

Copies to:  
Gregory Sichenzia, Esq.  
Jeff Cahlon, Esq.  
Sichenzia Ross Friedman Ference LLP  
61 Broadway  
New York, New York 10006  
Phone: (212) 930-9700  
Fax: (212) 930-9725

(Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.**

On November 13, 2015, the board of directors of DelMar Pharmaceuticals, Inc. (the “Company”) concluded that the Company’s previously issued financial statements, for the years ended June 30, 2015 and June 30, 2014, for each of the quarters in the years then ended as well as the quarters ended March 31, 2013 and June 30, 2013, should no longer be relied upon because of an error in such financial statements. In connection with the preparation of the Company’s financial statements for the three months ended September 30, 2015, and following consultation with a third party accounting consultant, the Company determined that the common stock purchase warrants issued by the Company for placement agents services on March 6, 2013 (the “Placement Agent Warrants”) represented a derivative liability and should not have been recognized as equity because the exercise price of the Placement Agent Warrants is subject to adjustment in certain circumstances. The reclassification of the Placement Agent Warrants does not affect the Company’s operations nor does it affect the Company’s working capital. The Company’s audit committee has discussed this matter with the Company’s independent accountant and re-stated financials have been prepared accordingly.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DELMAR PHARMACEUTICALS, INC.**

Dated: November 16, 2015

By: /s/ Jeffrey Bacha

Name: Jeffrey Bacha

Title: Chief Executive Officer